CGBio Shares 400 Cases of Fracture Treatment with "NOVOSIS"

Accelerating Global Market Expansion with Robust Clinical Evidence

CGBio, a company specializing in regenerative medicine, announced on September 1 that it successfully concluded the global seminar "Meet the Masters in Bangkok 2025 (Beyond Technique, Toward Healing: Trauma Meet the Masters in Bangkok 2025)" at the Millennium Hilton Hotel in Bangkok, Thailand, focusing on the treatment of fractures and trauma.

Group photo on site at 'Trauma Meet the Master in Bangkok 2025' hosted by CG Bio. CG Bio

Now in its fourth year, Meet the Masters was organized to share the latest trends in trauma treatment and strategies for applying CGBio's innovative bone graft substitute "NOVOSIS." Sixty-two orthopedic surgeons from Asian countries including South Korea, Thailand, Singapore, and Indonesia attended the event, where they discussed treatment strategies based on approximately 400 clinical cases, including complex and refractory fractures with complications.

As speakers, Professor Cho Wontae of Ajou University Hospital presented on "Application of NOVOSIS in the Treatment of Fracture-Related Bone Defects," offering methods for application based on the location and size of the defect, as well as post-surgical recovery management strategies. In addition, Dr. Renaldi Prasetia from Indonesia (nonunion of clavicle and proximal humerus), Professor Rahat Jarayaband from Thailand (post-traumatic segmental bone injury), Dr. Kevin Yik from Singapore (use of rhBMP-2 in trauma surgery), Dr. Ade Junaidi from Indonesia (complications of complex femoral fractures), and Dr. Noratep Kulachote from Thailand (refractory fracture healing) each presented significant cases from their respective countries, sharing a wide range of treatment experiences.

Professor Rahat Jarayaband of Bhumibol Adulyadej Hospital in Thailand, who chaired the symposium, emphasized, "NOVOSIS is an effective surgical material that can accelerate patient recovery when combined with the physician's clinical considerations and strategic techniques, such as infection management, bone fragment fixation, and surgical approach."

NOVOSIS is the world's second and Korea's first bone graft substitute loaded with recombinant human bone morphogenetic protein-2 (rhBMP-2). Based on porous hydroxyapatite (HAp) ceramic, which closely resembles human bone, it stably and continuously releases bone morphogenetic protein over several months, inducing bone regeneration. In particular, it is designed to minimize ectopic bone formation (the growth of bone in abnormal locations), making it suitable for use in trauma, spine, and orthopedic fields.

Meanwhile, based on the accumulated evidence of NOVOSIS's effectiveness in treating traumatic fractures, a dedicated brand lineup for traumatic fracture patients, "NOVOSIS Trauma," received product approval last year. NOVOSIS Trauma is a product line under the NOVOSIS brand for patients with severe injuries such as traumatic fractures, bone defects, and nonunion. As clinical evidence continues to build, global market demand is expanding. Earlier this year, CGBio signed an exclusive supply and distribution agreement with Johnson & Johnson MedTech for NOVOSIS and NOVOSIS Trauma in major Asian countries including South Korea and Thailand, marking the start of a full-scale expansion of overseas supply.

Yoo Hyunseung, CEO of CGBio, stated, "Through the 400 clinical cases and various challenging cases from different countries using our innovative bone graft substitute NOVOSIS, we have once again demonstrated the therapeutic efficacy and global competitiveness of NOVOSIS. Based on this, we will accelerate our efforts to expand into global markets and improve the standard of patient care."